What is Code Bio?
Founded in 2020, Code Bio is dedicated to transforming the treatment landscape for patients suffering from debilitating genetic diseases. The company's core innovation lies in its novel non-viral gene delivery platform, which is engineered to overcome the limitations of existing viral-based vectors. This technology is specifically designed to handle large gene payloads, offering a versatile and scalable approach to treating a wide array of indications. By prioritizing safety and efficacy, Code Bio aims to provide meaningful therapeutic outcomes for conditions that currently lack effective interventions, thereby establishing a strong competitive moat in the high-growth gene therapy sector.
How much funding has Code Bio raised?
Code Bio has raised a total of $85M across 2 funding rounds:
Angel/Seed
$10M
Series A
$75M
Angel/Seed (2021): $10M with participation from 4BIO Capital, JDRF T1D Fund, CureDuchenne, Takeda Pharmaceutical, New Enterprise Associates, and UPMC
Series A (2022): $75M led by Takeda, UPMC, New Enterprise Associates, CureDuchenne Ventures, 4BIO Capital, Hatteras Venture Partners, Northpond Ventures, Amgen Business Development, UCB Ventures, and JDRF T1D Fund
Key Investors in Code Bio
Takeda
A global pharmaceutical leader with a deep focus on gastroenterology, oncology, and rare diseases, leveraging extensive R&D capabilities to advance innovative healthcare solutions.
New Enterprise Associates
A prominent venture capital firm established in 1977, specializing in supporting entrepreneurs and scaling high-growth businesses across the technology and life sciences sectors.
4BIO Capital
A London-based venture capital firm dedicated to life sciences, focusing on advanced therapies including gene and RNA-based treatments to address significant unmet medical needs.
What's next for Code Bio?
With the infusion of recent capital, Code Bio is well-positioned to accelerate its research and development pipeline, moving closer to clinical validation. The strategic focus will likely center on scaling manufacturing capabilities and expanding the application of its delivery platform across diverse genetic targets. As the company matures, the emphasis will shift toward establishing key partnerships with global pharmaceutical entities to navigate the complex regulatory landscape and bring these innovative therapies to market. The continued support from institutional investors suggests a long-term commitment to building a sustainable, high-impact biotechnology enterprise capable of redefining standards of care for rare and complex genetic disorders.
See full Code Bio company page
